Barclays on Thursday downgraded the contract research organizations IQVIA Holdings (NYSE:IQV), ICON PLC (NASDAQ:ICLR), and Fortrea Holdings (NASDAQ:FTRE), arguing that the Trump administration’s ...

Barclays downgraded Iqvia (IQV) to Equal Weight from Overweight with a price target of $170, down from $235. The firm moved to the sidelines on ...

BofA lowered the firm’s price target on Iqvia (IQV) to $190 from $235 and keeps a Buy rating on the shares. Sentiment for Life Sciences and ...

Fintel reports that on April 10, 2025, Barclays downgraded their outlook for IQVIA Holdings (NYSE:IQV) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 58.50% Upside As of April 2, ...

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life ...

Shares of IQVIA Holdings Inc. IQV slipped 8.79% to $143.22 Thursday, on what proved to be an all-around poor trading session ...

IQVIA Holdings Inc. closed 42.44% below its 52-week high of $252.88, which the company reached on August 29th.

Barclays on Thursday downgraded the contract research organizations IQVIA Holdings (NYSE:IQV), ICON PLC (NASDAQ:ICLR), and Fortrea Holdings (NASDAQ:FTRE), arguing that the Trump administration’s ...

IQVIA Holdings Inc. provides clinical research ... It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sciences industries, has been named to the ...